Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of Descitabine Enhanced Infusion of Autologous DC-CIK Cells as a Post-remission Treatment for Malignant Tumors

NCT04292769 is registered in ClinicalTrials.gov with Li Yu as lead sponsor.

NCT NCT04292769
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04292769 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of Descitabine Enhanced Infusion of Autologous DC-CIK Cells as a Post-remission Treatment for Malignant Tumors
Lead sponsor
Li Yu
Phase
Phase 3
Overall status
Unknown status
Start date
January 21, 2020
Completion date
January 20, 2023
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant neoplasm